S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
OPTIC Trial Dose-Optimization Strategy
Elias Jabbour summarizes OPTIC's randomized dosing (45→15, 30→15, 15) with primary endpoint BCR-ABL ≤1% at 12 months.
Play episode from 05:59
Transcript
